GAAP EPS loss widened to $(0.41), reflecting higher R&D spending and no revenue. R&D expenses increased to $18.4 million (GAAP), compared to $14.6 million for Q2 2024, as PMV Pharmaceuticals advanced ...
PMV Pharmaceuticals, Inc. reported a corporate update and financial results for the first quarter of 2025, focusing on the ongoing Phase 2 PYNNACLE clinical trial evaluating rezatapopt, a treatment ...
Oral presentation to highlight initial data from ongoing pivotal Phase 2 study of rezatapopt, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors ...
PMV Pharmaceuticals has pressed pause on two preclinical tumor candidates to funnel all resources into getting its lead precision oncology med through the clinic. The “primary focus” of PMV is now the ...
PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of ...
PRINCETON, N.J., Feb. 11, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic ...
PMV Pharmaceuticals specializes in therapies that target the p53 protein, a “guardian of the genome” with a direct role in preventing cancer growth. Its research aims to restore the tumor suppressor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results